Newly Diagnosed
Trial No. Principal Investigator Trial Name
ECOG E1A11 Nattam Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
TRIO-US BMS CA209-602 Epstein An open-label, randomized phase 3 study of combinations fo Nivolumab, Elotuzumab, Pomalidomide and Desamethasone in relapsed and refractory Multiple Myeloma